^
Association details:
| Biomarker: | ATRX mutation |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | Koselugo (selumetinib) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting ATR and the ERK Pathway in High-grade Solid Tumors with Concurrent NF1 and ATRX Loss
Published date:
05/29/2021
Excerpt:
...a NF1-associated ATRX mutant glioblastoma cell line (JHH-CRC64)...JHH-CRC64 cell line demonstrated sensitivity to AZD6244 (MEK inhibition) but not AZD6738 (ATR inhibition).
DOI:
https://doi.org/10.1093/jnen/nlab042
